Ultragenyx Pharmaceutical Inc RARE

US Biotechnology

$14.50 ▼ -1.83% ($-0.27)

⬇️ Below Yest. Low

Open $14.87

Prev Close $14.77

Day Range $14.15 – $14.94

52W Range $12.73 – $39.89

Market Cap $1.43B

Beta 0.34

EPS (TTM) $-5.84

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2014-01-31
Shares Out.	98,490,000
Website	ultragenyx.com/ ↗
Phone	13026587581
Employees	1,371
Revenue	$214.0M
Gross Profit	$180.0M
Net Income	-$92.0M
Free Cash Flow	-$489.5M
Total Assets	$1.26B
Total Liabilities	$1.55B
Equity	-$284.0M

About Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

Ultragenyx Pharmaceutical Inc is a publicly traded company under the ticker symbol RARE on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.